Amphastar Pharmaceuticals
AMPH
135 hedge funds and large institutions have $477M invested in Amphastar Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 51 reducing their positions, and 13 closing their positions.
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
5% more funds holding
Funds holding: 129 → 135 (+6)
0.17% more ownership
Funds ownership: 54.73% → 54.89% (+0.17%)
9% less capital invested
Capital invested by funds: $523M → $477M (-$45.8M)
16% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 51
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $429K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.33M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.01M |
| 3 |
Goldman Sachs
New York
|
+$3.09M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.98M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$8.58M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$4.52M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.76M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.2M |
| 5 |
Renaissance Technologies
New York
|
-$1.62M |
AMPH Hedge Fund Activity: Q1 2021 in Review
135 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2021, worth a combined $477M — down 8.8% from $523M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AMPH positions and 13 closed out — a net gain of 7 holders — while 43 added to existing stakes and 51 trimmed.
The largest buyer was BlackRock, adding an estimated $4.33M. The largest seller was Invesco, cutting an estimated $8.58M.
- 135 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2021, up from 129 in Q4 2020.
- Funds reported $477M of Amphastar Pharmaceuticals stock for Q1 2021, down 8.8% quarter-over-quarter.
- 20 funds opened new Amphastar Pharmaceuticals positions in Q1 2021 and 13 closed out, a net change of +7 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2021 was BlackRock, an estimated $4.33M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2021 was Invesco, an estimated $8.58M sold.
Based on aggregated 13F filings for Q1 2021.